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Abstract
Background: North Sea Progressive Myoclonus Epilepsy is a rare and severe disorder caused by mutations in the
GOSR2 gene. It is clinically characterized by progressive myoclonus, seizures, early-onset ataxia and areflexia. As in
other progressive myoclonus epilepsies, the efficacy of antiepileptic drugs is disappointingly limited in North Sea
Progressive Myoclonus Epilepsy. The ketogenic diet and the less restrictive modified Atkins diet have been proven
to be effective in other drug-resistant epilepsy syndromes, including those with myoclonic seizures. Our aim was to
evaluate the efficacy of the modified Atkins diet in patients with North Sea Progressive Myoclonus Epilepsy.
Results: Four North Sea Progressive Myoclonus Epilepsy patients (aged 7–20 years) participated in an observational,
prospective, open-label study on the efficacy of the modified Atkins diet. Several clinical parameters were assessed at
baseline and again after participants had been on the diet for 3 months. The primary outcome measure was health-
related quality of life, with seizure frequency and blinded rated myoclonus severity as secondary outcome measures.
Ketosis was achieved within 2 weeks and all patients completed the 3 months on the modified Atkins diet. The diet
was well tolerated by all four patients. Health-related quality of life improved considerably in one patient and showed
sustained improvement during long-term follow-up, despite the progressive nature of the disorder. Health-related
quality of life remained broadly unchanged in the other three patients and they did not continue the diet. Seizure
frequency remained stable and blinded rating of their myoclonus showed improvement, albeit modest, in all patients.
Conclusions: This observational, prospective study shows that some North Sea Progressive Myoclonus Epilepsy
patients may benefit from the modified Atkins diet with sustained health-related quality of life improvement. Not all
our patients continued on the diet, but nonetheless we show that the modified Atkins diet might be considered as a
possible treatment in this devastating disorder.
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Background
North Sea Progressive Myoclonus Epilepsy (NSPME) is a
rare but devastating disorder clinically characterized by
progressive myoclonus, seizures, early-onset ataxia and are-
flexia. In the great majority of patients NSPME is caused by
the same homozygous c.430G >T (p.Gly144Trp) mutation
in the GOSR2 gene, first reported in 2011 [1]. In 2013
Boissé Lomax and colleagues coined the term NSPME, as
all the patients described came from countries bounding
the North Sea [2].
The clinical picture of NSPME is dominated by spon-
taneous and action-induced myoclonic jerks and ataxia,
which have a severe impact on daily functioning [3]. Most
NSPME patients also have generalized tonic or tonic-
clonic seizures, albeit that the seizures are relatively mild
compared to the myoclonic jerks. Both myoclonic jerks
and seizures can be treated with anti-epileptic drugs, but
the benefits are disappointingly limited. Progressive myo-
clonic epilepsies, as a group, are not amenable to epilepsy
surgery [4]. Vagus nerve stimulation can lead to seizure
reduction, but does not help control the myoclonus [5].
This absence of an effective treatment for NSPME served
as an impetus for exploring alternative treatment options.
The ketogenic diet (KD) has been proven to be effective
in other drug-resistant epilepsy syndromes [6, 7], includ-
ing those with myoclonic seizures [8, 9]. The modified
Atkins diet (MAD) is a less restrictive variant of the
classical KD and has shown similar benefits in seizure
disorders [10]. The KD is a high-fat, low-carbohydrate
diet. In contrast to the classical KD, the MAD does not
restrict protein- or calorie-intake. The MAD is therefore
easier to maintain, facilitating long-term compliance,
especially in adolescents and young adults [11].
Our aim was to evaluate the efficacy of the MAD in
patients with NSPME by measuring health-related qual-
ity of life (HRQL) as the primary outcome.
Methods
Participants
Four NSPME patients aged between 7 and 20 years, all
with the known c.430G > T (p.Gly144Trp) mutation, par-
ticipated in an observational, prospective, open-label study
on the efficacy of the MAD in the University Medical
Centre Groningen (UMCG) for 3 months (February to
May 2013). They were 7, 12, 20 and 20 years old at the
start of the trial. We offered six patients treatment with
MAD, but two decided not to start with the diet. The
study was performed according to the legal and ethical
guidelines of the UMCG’s medical ethics committee.
Modified Atkins diet
Pre-evaluation was made and dietary instructions given ac-
cording to the recommendations of the international keto-
genic diet study group during a 3-day hospital admission
[12]. The MAD that was applied included a carbohydrate
intake restriction, initially of 0.4 g per kilogram body weight,
together with administration of the ketogenic formula:
KetoCal 4:1 LQ®/ 12 ml per kilogram body weight. Fat and
protein intake were unlimited. The diet was initiated step-
wise at home over 7–10 days without fasting. When ketosis
was adequately stabilized, carbohydrate intake was increased
stepwise by 5 g per day as long as ketosis persisted. Patients
were allowed to take extra carbohydrates, on the condition
of taking 4 g extra fat for every gram carbohydrate. Blood
ketones and glucose were assessed by twice-daily home
monitoring for at least the first month. After the first month
stable ketosis had been reached in all patients and blood
ketones and glucose measurements were gradually reduced
from twice a day to eventually only once a week. On indica-
tion patients or their caregivers performed additional sam-
pling of glucose and ketones.
Our dieticians helped the caregivers to offer a wide
selection of alternative products to the patients. For
instance written dietary exchange lists were provided,
and patients were allowed to compensate the carbohy-
drate intake with fat emulsion, so they could choose
their preferred dietary products.
During the first 6 weeks, the patients visited our multidis-
ciplinary outpatient clinic every 2 weeks. In addition, at
least once a week the dieticians had an telephone or e-mail
consultation with the patients or their caregivers, or more
frequently when necessary (sometimes daily contact).
Data collection
To evaluate the efficacy of the MAD we assessed several
clinical parameters at baseline and after 3 months on the
diet. HRQL was assessed by using the Dutch Generic Core
Scale of the Paediatric Quality of Life Inventory (PedsQL)
4.0 [13]. Each patient completed the age-specific version
of the PedsQL and, in addition, the parents of the two
paediatric patients completed the PedsQL parent proxy
report. The PedsQL questionnaire asks patients and their
parents to indicate to what extent the patient encountered
problems in the last few months before baseline in phys-
ical, emotional, social and school-related domains.
From 4 weeks before baseline up until the end of the
study, the patients and/or their parents recorded the
seizure frequency in a daily diary. They also recorded
any adverse effects of the diet and their perception of
the myoclonus severity on a 10-point scale. In addition,
an EEG and blinded rating of the myoclonus severity
were performed at baseline and after 3 months. For the
myoclonus rating we performed a videotaped examin-
ation using a standardized protocol. These videos were
scored by two independent raters (JG and RZ), blinded
for the condition of the patient (baseline or on the diet);
they used the Unified Myoclonus Rating Scale (UMRS)
[14] and the Clinical Global Impressions Scale [15].
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Furthermore, questionnaires were used to assess mood
and behaviour. The self-rated version of the Inventory of
Depressive Symptomatology (IDS) was used for the two
adolescent patients [16]. Mood and behaviour in the two
youngest patients were measured by a neuropsychologist
consultation, with the Child Behaviour Check List
completed by the parents, the Youth Self Report com-
pleted by the patients, and the Caregiver Teacher Report
Form, completed by the school teacher. An occupational
therapist used the Canadian Occupational Performance
Measure (COPM) to identify and prioritize issues that
restricted the patient’s performance in everyday living;
this provided the basis for setting intervention goals
[17]. After 3 months, changes in the patient’s self-
perception of occupational performance were also evalu-
ated with the COPM.
Results
Patient characteristics are shown in Table 1. A detailed
description of their clinical phenotypes has been reported
elsewhere [3].
All patients completed a 3-months period on the MAD.
The diet was well tolerated and none of the patients re-
ported major side-effects. During this period there were
no relevant changes in medication or in weight. The pa-
tients received 15, 19, 17 and 35 g of carbohydrates/day
respectively, which was also based on bodyweight. Ketosis
was reached within 2 weeks in all patients, but significant
ketosis was only observed in the youngest patient (patient
4). He became ketotic after just five days on the diet and
had average ketones of 4.3 mmol/L (range 2.5–6.6 mmol/
L). The other child (patient 1) had average ketones of
2.3 mmol/L (range 1.3–3.7 mmol/L), while the two young
adults had average ketones of 2.2 mmol/L (range 0.8–
4.4 mmol/L) and 2.6 mmol/L (range 1.3–3.5 mmol/L), re-
spectively. Stable ketosis was somewhat easier to achieve
in the two youngest patients.
The results of the assessments at baseline and after 3
months on the diet are shown in Table 2. Patient 1 and
his mother reported a 40% and 13% improvement in
HRQL, respectively. The HRQL scores of patient 3 and
4 also showed improvement (5% and 14% respectively).
Patient 2 and the parents of patient 4 reported a deteri-
oration of the HRQL (19% and 39% respectively).
Blinded rating of myoclonus (UMRS), showed small
but positive changes in all patient scores (both in rest
and in action). The most evident improvements in
UMRS score were seen in patients 1 and 2 (aged 12 and
20 years). Seizure frequency remained stable in the three
patients who suffered from seizures.
The EEGs of the four patients did not show a relevant
decrease of epileptic discharges while on the MAD.
Although patient 4 had presented no clinical seizures and
only myoclonus and ataxia, his EEG did show epileptic ac-
tivity and this did not change during the diet period. The
results of the complementary assessments of mood, behav-
iour and occupational performance did not show relevant
changes in the younger children, but the two adolescent pa-
tients reported negative effects. They felt more depressed
due to the restricted diet, in particular they missed specific
foods such as bread and potatoes in their daily diet. Their
IDS-score declined by 7 and 8 points, respectively. Because
the benefits did not match the efforts of maintaining the
diet due to its restrictions, patients 2, 3 and 4 discontinued
the MAD after a duration of 3, 3 and 5 months, respect-
ively. The provided wide variation of alternative products
and menus, and the intensive support from our dieticians
could not prevent discontinuation. The parents of the
youngest patient (patient 4, aged 7 years) said they would
consider to restart the MAD in the future if their child’s
symptoms would become more severe.
To date, patient 1 is still on the MAD and his HRQL and
blinded rating of myoclonus were reassessed after 3 years
on the diet. Compared to the baseline measures, he
reported the same HRQL, while his parents reported a sus-
tained improvement of 25%, despite the progressive nature
of the disorder. In parallel, the UMRS scores at three years
remained broadly unchanged compared to baseline. He
showed an improved and sustained physical fitness on the
diet, and he recently switched from a school for physically
handicapped children to regular secondary education.
Discussion and conclusion
Worldwide only 21 NSPME patients have been described
[1–3]. In this observational prospective study, we evaluated
the efficacy of the MAD in four NSPME patients, with
HRQL as our primary outcome measure. In our study one
of the four patients showed an improved HRQL on the diet.
Table 1 Baseline characteristics of the patients
Patient Sex Agea Motor function Seizures EEG Medical treatment
1 M 12 Ambulant Clonic seizures GED, PCR CLN, LEV, VPA
2 M 20 Ambulant + wheelchair Tonic seizures GED, PCR CLN, ESM, LEV, VPA
3 M 20 Wheelchair GTCS GED, PCR CLN, ESM, LEV, VPA
4 M 7 Ambulant No GED, PCR None
aAge at start modified Atkins diet
Abbreviations: CLN Clonazepam, EEG Electroencephalography, ESM Ethosuximide, GED Frequent generalized epileptic discharges, GTCS Generalized tonic-clonic
seizures, LEV Levetiracetam, M Male, PCR Photoconvulsive response, VPA Valproic acid
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This 12-year old boy reported a significant (40%) improve-
ment in his HRQL after 3 months on the MAD. He
decided to continue on the diet because he felt healthier
and less tired, experienced less jerking in the evening and
less nocturnal shaking, and could participate more at
school and in social events. After 3 years on the MAD, his
HRQL has stabilized compared to his baseline, despite the
progressive nature of the disease. The other three patients
reported varied changes in their HRQL and UMRS while
on the diet, but all decided to stop after 3 to 5 months
because the benefits were perceived to be too limited
compared to their dietary restrictions.
Ketosis in the youngest patient (#4) was excellent while
he was on the MAD; compared to the other patients he
had milder myoclonus and no clinical seizures, but a com-
parable HRQL to patient 2, for instance. In this respect it
was interesting to observe that his parents thought the
burden of the diet was more relevant than the reduction
in his myoclonus: they reported a deterioration in the
HRQL. However, the patient himself reported a consider-
able improvement in his HRQL questionnaires, which il-
lustrates that the parents and patient experienced the
diet’s burden differently, and this influenced their decision
to continue the dietary treatment (Table 2).
The levels of plasma ketones of patient 1 were similar
to those of patient 2 and 3. The benefit of the MAD ob-
served in patient 1 and lack of benefit in patients 2 and
3 are therefore unlikely to be due to differences in the
degree of ketosis achieved during the first 3 months.
Seizure frequency remained stable in all four patients while
on the diet. Although epilepsy was not their main symptom,
three of the four patients had generalized tonic, clonic or
tonic-clonic seizures with a mean frequency of once a week.
Neither the patients nor their parents reported a relevant
decrease of seizure frequency while on MAD. EEG findings
did not show a change in the epileptic discharges in any of
the patients while on the MAD. The UMRS scores showed
small, but positive, changes in all the patients on the diet, and
the scores of patient 1 at 3 years remained broadly un-
changed compared to his baseline, which is remarkable given
the progressive nature of the disorder.
Reports on the effect of treatment with the KD in PME
are scarce. The KD seems to be particularly effective in
generalized forms of epilepsy, including epilepsies with
myoclonus [9, 18]. The response rates in the randomized
controlled trials of Neal et al. and Lambrechts et al. [6, 7]
in children with refractory epilepsy were 38% and 50% re-
spectively, with the percentage of patients who had >50%
seizure reduction as the primary outcome measure. In our
patients, not epilepsy but myoclonus was the major symp-
tom, reported to interfere most with their activities of
daily living. This makes it difficult to compare our results
of the controlled KD trials. Despite our study showing im-
provement in only one out of four patients, for this single
case MAD made a major and sustained difference to his
HRQL and this was thus an excellent treatment result.
We chose HRQL as the main outcome measure and not
seizure frequency or UMRS scores because we considered
the sole use of impairment-focused measures to be too
limited in scope to evaluate the overall effects of the diet
effectively. It has been shown that disease severity rating
scales might not always be suited to evaluating the overall
effects of an intervention [19], and in small groups of pa-
tients it is difficult to detect minor differences on disease
severity scales [20]. For these reasons we chose HRQL as
our primary endpoint [19, 20]. Koy et al. supported this
idea; they described how quality of life can improve
significantly in children after deep brain stimulation for
dystonia due to cerebral palsy, without any improvement
shown on rating scales [21]. Moreover, HRQL likely in-
cludes all the different aspects of treatment sequelae in
this very rare disorder, and importantly also takes into
Table 2 Results of the assessments at baseline and at 3 months on the Modified Atkins Diet in four patients with North Sea
Progressive Myoclonus Epilepsy
Patient HRQLa UMRSb Effect on seizure
frequencyc
EEG changec Changes in mood
and behaviourcBaseline MAD at
3 months
Change MAD at
3 years
Baseline MAD at
3 months
Change MAD at
3 years
1 pt. 46 pt. 27 impr. 19 pts pt 47 71 64 impr. 7 pts 75 No change No changes n.d.
par. 50 par. 43 impr. 7 pts par. 37
2 25 31 det. 6 pts n.a. 72 58 impr. 14 pts n.a. No change No changes det. IDS 7 pts
3 58 55 impr. 3 pts n.a. 87 85 impr. 2 pts n.a. No change n.d. det. IDS 8 pts
4 pt. 28 pt. 24 impr. 4 pts n.a. 57 56 impr. 1 pts n.a. n.a No changes no relevant change
par. 19 par. 31 det. 12 pts
ascores were calculated by the sum of all scores divided by the number of answered items (maximum score 92). A lower score represents a better HRQL
bUMRS: scores represent the sum scores of section 2, 3 and items A-G of section 4 of the UMRS, calculated by using the UMRS score sheet [14]. A lower score
represents less myoclonus; for patient 2, 3 and 4 the scores are the average scores of the two raters; for patient 1 the consensus scores of the two raters are
shown in the table (because in the individual scores there was one outlier, so a consensus meeting was organised where the raters rescored all videos together)
cchange between baseline assessment and 3 months assessment during the MAD
Det. Deterioration, EEG Electroencephalography, HRQL Health-related quality of life, IDS Inventory of depressive symptomatology, impr. improvement, MAD
Modified Atkins diet, n.a. not applicable, n.d. no data, par. parents, pt. patient, pts points, UMRS Unified Myoclonus Rating Scale
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account the influence of the diet’s restrictions on the pa-
tient’s well-being. This is well illustrated by patient 2, in
which an improvement of almost 20% was observed in
blinded rating of his myoclonus, but the improvement
was counteracted by a deterioration in his mood and a de-
pressed state due to the diet.
There are several limitations to our study. First, we
were only able to evaluate four patients and could not
include a control group. However, given the rarity of
NSPME and the number of patients reported worldwide
with this disorder (n = 21), four patients is still a good
size group to study. Second, the duration of follow-up of
three of the four patients was relatively short because
they decided to discontinue the diet.
In conclusion, this observational study shows that one
out of four patients with NSPME had a favourable re-
sponse to the MAD. This patient, who was 12 years old
at the start of the study, has been on the diet for more
than three years and has a stable HRQL, despite his pro-
gressive disorder. Therefore, the MAD might be consid-
ered in patients with NSPME, as it may improve or
stabilize HRQL in this devastating disorder.
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